Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Nut Allergy Study: Double-blind Challenge and Oral Desensitization

This study has been completed.
Information provided by (Responsible Party):
Mika Juhani Mäkelä, MD, PhD, Helsinki University Central Hospital Identifier:
First received: May 27, 2011
Last updated: September 12, 2016
Last verified: September 2016
Nut sensitization in skin prick tests is common in areas, including Finland, where birch pollen is abundant. However, sensitization to nuts in skin prick test does not predict the possibility of allergic symptoms when nuts are ingested. In this study the investigators launch and perform double-blind placebo-controlled nut challenges and oral desensitization/ protocol to those with serious symptoms in the challenge. The efficacy and safety of the new oral desensitization program is the primary outcome. The effect of oral desensitization on bronchial hyperreactivity, eosinophilic airway inflammation, and quality of life are secondary outcomes.

Condition Intervention
Nut Allergy
Dietary Supplement: Nut challenge
Dietary Supplement: Nut challenge: Placebo
Dietary Supplement: Nut oral desensitization

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Nut Allergy Study: Improving Diagnosis And Treatment Of Nut Allergy

Resource links provided by NLM:

Further study details as provided by Helsinki University Central Hospital:

Primary Outcome Measures:
  • Efficacy of nut oral desensitization [ Time Frame: 7 months ]
    Change from baseline in the amount of nut (mg) tolerated in a double-blind placebo-controlled oral challenge at 1 month after the 6-month oral desensitization therapy.

Secondary Outcome Measures:
  • Effect of the treatment on quality of life [ Time Frame: 7 months ]
    Change from baseline in Quality of life questionnaire square before and after the oral desensitization therapy

  • Effect of the treatment on bronchial hyperreactivity and airway inflammation [ Time Frame: 1 year ]
    Change from baseline in bronchial hyperreactivity in metacholine challenge and in eosinophilic airway inflammation measured by multiple channel exhaled nitric oxid

  • Safety of nut oral desensitization therapy [ Time Frame: 7 months ]
    Number of participants with adverse events as a measure of safety and tolerability

  • Effect of the treatment on eosinophilic airway inflammation [ Time Frame: 1 year ]
    Change from baseline in exhaled nitric oxid concentration

Enrollment: 102
Study Start Date: May 2011
Study Completion Date: March 2016
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nut challenge
Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
Dietary Supplement: Nut challenge
Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
Other Names:
  • Super nuts banan chips
  • Yosa oat yoghurt
  • Arla cowpower chololate pudding
Placebo Comparator: Nut challenge: Placebo
See intervention
Dietary Supplement: Nut challenge: Placebo
Dried banana mixed with oat yoghurt or chocolate pudding
Other Names:
  • Super nuts banan chips
  • Yosa oat yoghurt
  • Arla cowpower chololate pudding
Experimental: Nut oral desensitization
Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
Dietary Supplement: Nut oral desensitization
Roasted peanut powder mixed with milk- and soy-free margarine
Other Names:
  • Old Virginia Byrd Mill Fat-Light roasted peanut
  • Keiju-margarine

Detailed Description:
The investigators aim to improve nut allergy diagnosis by launching a new double-blind placebo-controlled nut (peanut, hazel nut, cashew) challenge protocol. The investigators also launch a specific oral tolerance induction (SOTI) protocol to nuts in serious nut allergy. This study takes place in the Helsinki University Skin and Allergy Hospital between May 2011 and December 2015. Inclusion criteria: age 6 to 18 years and suspected nut allergy (unclear anaphylaxis possibly caused by nuts, skin prick test to nuts ≥ 10 mm or specific-IgE ≥ 20 kU/L and have never eaten nuts, or avoids nuts and does not dare try nuts at home). Patients having uncontrolled asthma or other lung disease, having cardiovascular disease or other systemic disease, using beta-blockers, and having poor compliance, are excluded. Methods:The investigators perform skin prick tests to peanut, tree nuts and seeds, take a blood sample before the double-blind placebo-controlled food challenges (DBPCFC), and measure total IgE and specific-IgE to birch, peanut, hazel nut, allergen components Ara h 1, 2, 3, and 8, and Cor a 1 and 8. Then the serum samples are kept frozen for further component and immunologic analyses. The investigators put iv before the challenge. In DBPCFC the patients receive 5 mg, 50 mg, 200mg, and 1000mg nut protein mixt with placebo, or placebo every 30 minutes. The severity of the allergic reaction is estimated using a modified severity scale. The probability of severe/moderate reaction at low (<0.7 kU/L) and at increased (>0.7 kU/L) Ara h 2 and 8 concentrations is the primary end-point in the DBPCFC. The investigators also correlate the concentrations of Ara h 2 with the severity score. Patients with moderate or severe reaction in the challenge will be offered desensitization therapy "SOTI" using(pea)nut flour mixed with milk-free margarine. The first dose of 0.1 mg nut protein is given at hospital part of the up-dosing is made at home every 2 weeks. The patient takes an antihistamine 1 hour before each daily dose. An epinephrine autoinjector and prednisolone tablets are also prescribed for emergency use. The desensitization protocol takes 28 weeks and is personalized when needed. Exercise is avoided 1 hour following each dose. Before and after the SOTI the investigators measure food related quality of life using standardized questionnaires, and perform metacholine challenge and measure exhaled nitric oxid. After the SOTI the investigators take blood samples and perform DBPCFC again.

Ages Eligible for Study:   3 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • sensitization in skin prick test or in serum nut-specific IgE
  • unknown anaphylaxis suspected caused by nuts
  • never eaten nuts
  • if challenge positive with serious symptoms, OIT

Exclusion Criteria:

  • active asthma and low lung function,
  • pregnancy, cardiovascular or other disease that might worsen during the challenge and OIT
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01502878

Helsinki University Central Hospital, Skin and Allergy Hospital
Helsinki, Finland, 00029
Helsinki University Central Hospital, Skin and Allergy Hospital
Helsinki, Finland, 160
Sponsors and Collaborators
Helsinki University Central Hospital
Principal Investigator: Mika J Mäkelä, MD, PhD Helsinki UCH
  More Information

Responsible Party: Mika Juhani Mäkelä, MD, PhD, Chief Physician, Helsinki University Central Hospital Identifier: NCT01502878     History of Changes
Other Study ID Numbers: HUCHT101060080
IAS11 ( Registry Identifier: HUCH, Skin and Allergy Hospital )
Study First Received: May 27, 2011
Last Updated: September 12, 2016

Keywords provided by Helsinki University Central Hospital:
Nut allergy
Double-blind placebo-controlled (DBPC) oral nut challenge
Nut oral immunotherapy (OIT)
Nut oral desensitization

Additional relevant MeSH terms:
Nut Hypersensitivity
Immune System Diseases
Food Hypersensitivity
Hypersensitivity, Immediate processed this record on May 23, 2017